龍泉股份(002671.SZ):子公司預中標6732.93萬元示範快堆工程1、2號機組小口徑(≤DN400)核級涉鈉無縫管件及彎管採購項目
格隆匯10月11日丨龍泉股份(002671.SZ)公佈,近日,中國招標投標公共服務平台發佈了《示範快堆1、2號機組小口徑(≤DN400)核級涉鈉無縫管件及彎管採購項目中標候選人公示》,確定山東龍泉管道工程股份有限公司之全資子公司無錫市新峯管業有限公司(“新峯管業”)為“示範快堆工程1、2號機組小口徑(≤DN400)核級涉鈉無縫管件及彎管採購項目”中標候選人第一名。
此次投標報價合計為人民幣6732.93萬元,約佔公司2020年度經審計營業收入的8.05%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.